IN2012DN05186A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05186A
IN2012DN05186A IN5186DEN2012A IN2012DN05186A IN 2012DN05186 A IN2012DN05186 A IN 2012DN05186A IN 5186DEN2012 A IN5186DEN2012 A IN 5186DEN2012A IN 2012DN05186 A IN2012DN05186 A IN 2012DN05186A
Authority
IN
India
Prior art keywords
amyloids
diseases
disease
detection
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Jerry Yang
Emmanuel A Theodorakis
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IN2012DN05186A publication Critical patent/IN2012DN05186A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/28—Nitrogen atoms
    • C07D295/30—Nitrogen atoms non-acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IN5186DEN2012 2009-12-10 2010-12-10 IN2012DN05186A (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28547009P 2009-12-10 2009-12-10
PCT/US2010/059952 WO2011072257A2 (en) 2009-12-10 2010-12-10 Amyloid binding agents

Publications (1)

Publication Number Publication Date
IN2012DN05186A true IN2012DN05186A (xx) 2015-10-23

Family

ID=44146211

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5186DEN2012 IN2012DN05186A (xx) 2009-12-10 2010-12-10

Country Status (26)

Country Link
US (3) US8940918B2 (xx)
EP (1) EP2509940B1 (xx)
JP (1) JP5591946B2 (xx)
KR (3) KR20180041767A (xx)
CN (2) CN103201258B (xx)
AU (1) AU2010327918B2 (xx)
BR (1) BR112012013810B1 (xx)
CA (1) CA2783466C (xx)
CY (1) CY1116487T1 (xx)
DK (1) DK2509940T3 (xx)
ES (1) ES2546063T3 (xx)
HK (2) HK1177930A1 (xx)
HR (1) HRP20150854T1 (xx)
HU (1) HUE027199T2 (xx)
IN (1) IN2012DN05186A (xx)
ME (1) ME02194B (xx)
MX (1) MX347591B (xx)
NZ (1) NZ600459A (xx)
PL (1) PL2509940T3 (xx)
PT (1) PT2509940E (xx)
RS (1) RS54158B1 (xx)
RU (1) RU2517174C2 (xx)
SG (1) SG181561A1 (xx)
SI (1) SI2509940T1 (xx)
SM (1) SMT201500216B (xx)
WO (1) WO2011072257A2 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013180815A1 (en) * 2012-05-30 2013-12-05 University Of Tennessee Research Foundation Compounds for amide-forming reactions
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
TW201609183A (zh) 2013-10-31 2016-03-16 康諾普堤克斯公司 眼用調配物之製備方法及其用途
CA2930112A1 (en) * 2013-11-12 2015-05-21 Cognoptix, Inc. Method for measuring fluorescence in ocular tissue
EP3119761B1 (en) * 2014-03-19 2023-06-07 Amydis Diagnostics, Inc. Amyloid targeting agents and methods of using the same
CA2960723A1 (en) * 2014-09-12 2016-03-17 Amydis Diagnostics, Inc. In vitro compositions comprising human sample and amyloid targeting agent
WO2018208709A1 (en) 2017-05-09 2018-11-15 Warner Babcock Institute For Green Chemistry, Llc Stilbene derivatives for the treatment of cns and other disorders
WO2019232422A1 (en) * 2018-05-31 2019-12-05 Amydis, Inc. Compositions and methods for detection of traumatic brain injury
US20220001033A1 (en) 2018-11-02 2022-01-06 Amydis, Inc. Phosphate compounds for detecting neurological disorders
IL305647A (en) * 2021-03-12 2023-11-01 Amydis Inc Methods for the detection of systemic amyloidosis by binding to misfolded protein or aggregates
CN115322165A (zh) * 2022-09-30 2022-11-11 镇江百单医疗生物科技有限公司 近红外荧光探针成像肝纤维化中亚铁离子的动态波动

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2583614A (en) * 1950-05-13 1952-01-29 Eastman Kodak Co Acylated methine dye compounds
US2798090A (en) * 1953-03-02 1957-07-02 Eastman Kodak Co Process for preparing benzalaniline-3-sulfonic acid compounds
US3074971A (en) * 1959-01-23 1963-01-22 Gen Aniline & Film Corp alpha-cyanocinnamic acid esters
US3149146A (en) * 1960-03-09 1964-09-15 Gen Aniline & Film Corp Alpha-cyano-2-alkenoxy-1-naphthaleneacrylic acid esters
FR1321641A (fr) 1962-03-08 1963-03-22 Gen Aniline & Film Corp Nouvelles compositions absorbantes de rayons ultraviolets
BE794010A (fr) * 1972-01-13 1973-05-02 Du Pont Colorants cationiques de couleur jaune-vert
DE2714653C3 (de) 1977-04-01 1980-10-30 Bayer Ag, 5090 Leverkusen Kationische Styrylfarbstoffe und Verfahren zum Färben mit diesen Farbstoffen
DE2942185A1 (de) * 1979-10-18 1981-04-30 Basf Ag, 6700 Ludwigshafen Basische farbstoffe
JPS5815912A (ja) * 1981-07-22 1983-01-29 Ss Pharmaceut Co Ltd 消炎鎮痛剤
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS63163826A (ja) * 1986-12-26 1988-07-07 Idemitsu Kosan Co Ltd 有機非線型光学材料
DE3905916A1 (de) * 1989-02-25 1990-08-30 Basf Ag Verwendung von derivaten des n-phenyl-3,4,5,6-tetrahydrophthalimids zur desikkation und abszission von pflanzenorganen
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE4430691A1 (de) * 1994-08-30 1996-03-07 Bayer Ag Elektrolumineszierende Anordnungen und deren Verwendung
GB2401363B (en) * 2002-01-18 2005-10-12 Hospital For Sick Children Compounds for modulating cell proliferation
GB0228410D0 (en) * 2002-12-05 2003-01-08 Glaxo Group Ltd Novel Compounds
ZA200507321B (en) * 2003-03-05 2007-03-28 Celgene Corp Diphenylethylene compounds and uses thereof
US7517695B2 (en) * 2004-01-20 2009-04-14 The Curators Of The University Of Missouri Local flow and shear stress sensor based on molecular rotors
CA2560584A1 (en) * 2004-03-26 2005-10-06 Hsc Research And Development Limited Partnership Novel compounds for modulating cell proliferation
WO2006059245A2 (en) * 2004-11-16 2006-06-08 Neurochem (International) Limited Compounds for the treatment of cns and amyloid associated diseases
US7666886B2 (en) 2005-07-15 2010-02-23 The Regents Of The University Of California Compounds and methods for the diagnosis and treatment of amyloid associated diseases
CN101522300B (zh) 2006-07-31 2012-10-10 巴斯夫欧洲公司 适用于氢化的钌催化剂的再生方法
FR2905009A1 (fr) * 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
CN101209976B (zh) * 2006-12-29 2012-01-11 中国人民解放军军事医学科学院毒物药物研究所 取代的酒石酸衍生物及其用于制备β-分泌酶抑制剂的用途
WO2009052837A2 (en) * 2007-10-24 2009-04-30 Tallinn University Of Technology Maldi ms-based high-throughput screening method for substances inhibiting aggregation of alzheimer's amyloid beta peptides

Also Published As

Publication number Publication date
ES2546063T3 (es) 2015-09-18
BR112012013810A2 (pt) 2020-08-25
HK1177930A1 (en) 2013-08-30
HRP20150854T1 (hr) 2015-09-25
PT2509940E (pt) 2015-09-24
SG181561A1 (en) 2012-07-30
MX2012006552A (es) 2012-08-23
CY1116487T1 (el) 2017-03-15
HUE027199T2 (en) 2016-08-29
CA2783466A1 (en) 2011-06-16
NZ600459A (en) 2014-01-31
MX347591B (es) 2017-05-03
ME02194B (me) 2016-02-20
RU2517174C2 (ru) 2014-05-27
EP2509940B1 (en) 2015-06-10
WO2011072257A3 (en) 2011-10-20
BR112012013810B1 (pt) 2022-01-11
EP2509940A4 (en) 2013-04-17
AU2010327918A1 (en) 2012-06-21
CA2783466C (en) 2019-09-24
KR20120104306A (ko) 2012-09-20
CN103201258B (zh) 2016-01-27
US20170315137A1 (en) 2017-11-02
SI2509940T1 (sl) 2015-09-30
US20120302603A1 (en) 2012-11-29
CN103201258A (zh) 2013-07-10
CN105669597B (zh) 2019-05-07
PL2509940T3 (pl) 2015-11-30
RU2012128798A (ru) 2014-01-20
CN105669597A (zh) 2016-06-15
HK1225729A1 (zh) 2017-09-15
JP2013513619A (ja) 2013-04-22
WO2011072257A2 (en) 2011-06-16
KR20190109594A (ko) 2019-09-25
US9551722B2 (en) 2017-01-24
US8940918B2 (en) 2015-01-27
KR102079160B1 (ko) 2020-02-19
US20150177262A1 (en) 2015-06-25
JP5591946B2 (ja) 2014-09-17
AU2010327918B2 (en) 2014-01-16
SMT201500216B (it) 2015-10-30
KR101849680B1 (ko) 2018-04-17
DK2509940T3 (en) 2015-07-20
RS54158B1 (en) 2015-12-31
EP2509940A2 (en) 2012-10-17
KR20180041767A (ko) 2018-04-24

Similar Documents

Publication Publication Date Title
IN2012DN05186A (xx)
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
IL245889A0 (en) Sulfonamide derivatives as bcl-2-selective apoptosis inducers for the treatment of cancer and immune diseases
SI2104682T1 (sl) Diagnostika in zdravljenje Alzheimerjeve bolezni in drugih nevrodementnih bolezni
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
EP2519234A4 (en) ANAPLEROTIC THERAPY FOR ALZHEIMER'S DISEASE AND BRAIN AGING
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
WO2013033037A3 (en) Novel antiprion compounds
EP2429992A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EP2515926A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS-RELATED OPHTHALMIC DISEASES
EP2568811A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
IL237730B (en) Treatment of mild and moderate Alzheimer's disease
CA2851761C (en) Method of diagnosis, prognostic or treatment of neurodegenerative diseases
EP2398789A4 (en) SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2010105035A9 (en) Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
DE102009018133A8 (de) Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
GB2473579A (en) Stat3 and TYK2 as drug targets for neurodegenerative diseases
EP2391379A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2413696A4 (en) COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2565184B8 (en) Therapeutic agent and preventative agent for alzheimer's disease
NZ609924A (en) Porphyrin treatment of neurodegenerative diseases
ZA201402477B (en) Compounds for use in the treatment of alzheimer's disease
GB201206984D0 (en) New therapeutic use
EP2613849A4 (en) RADIOTHERAPY TO TREAT ALZHEIMER'S DISEASE